Xolv Creates a New Venture to Embark on New Era of Innovation in Behavioral Health
03 janv. 2024 16h53 HE
|
Xolv
WALNUT CREEK, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xolv, formerly Catalight’s IT and technology innovation group, proudly announces its transition to a new corporation today as part of a...
NeuroQure Acquires Patents to Detect Autism in Newborns with a Skin Sample
13 déc. 2023 09h30 HE
|
NeuroQure
IRVINE, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- NeuroQure, a pioneering biotech startup specializing in gene therapy for neurocognitive disorders, has reached a pivotal milestone in the...
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
24 nov. 2023 08h55 HE
|
SciSparc Ltd
TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
Study: Autistic Children May Need Fewer Hours of Treatment Than Previously Thought
21 nov. 2023 13h41 HE
|
Catalight
Walnut Creek, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Each year, tens of thousands of parents and caregivers of children with autism spectrum disorder (ASD) face vital decisions: What kind of...
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
20 nov. 2023 08h05 HE
|
Yamo Pharmaceuticals
Yamo Pharmaceuticals LLC has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents with autism spectrum disorder (ASD).
Catalight Honored as a Healthy People 2030 Champion from Department of Health and Human Services
15 nov. 2023 13h40 HE
|
Catalight
Walnut Creek, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Citing the company’s bold vision for the future, Catalight was recently named a Healthy People 2030 Champion by the Office of Disease...
Neurological Biomarkers Research Report 2023: A Global $18.75 Billion Market by 2030 with Pipeline Analysis of Alzheimer's, Parkinson's, Multiple Sclerosis, & Autism Spectrum Disorder
14 nov. 2023 05h28 HE
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type,...
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
06 nov. 2023 12h00 HE
|
NeuroQure
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum...
Hopebridge Launches Standardized Circle Time Curriculum in Autism Therapy Centers Across the Country
30 oct. 2023 08h00 HE
|
Hopebridge
Indianapolis, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Children with autism spectrum disorder (ASD) will now have even more support in their transition to school due to an innovative Circle Time Curriculum...
Axial Therapeutics Announces Completion of Enrollment in Global Phase 2b Clinical Trial for AB-2004 for Irritability Associated with Autism
26 sept. 2023 08h00 HE
|
Axial Therapeutics
– Topline clinical data anticipated in 1Q 2024 – – First-in-class small molecule therapeutic targets the microbiome gut-brain axis and its role in autism, offering a potential alternative to...